FDA outlines a psychedelic drug framework and holds its first public hearing

The U.S. Food and Drug Administration made two moves on psychedelic medicines within a week in September 2026. On September 9 and 10, senior FDA officials published what they called a "new framework for psychedelic drugs" in the New England Journal of Medicine (NEJM). Then on September 14, the agency held its first public hearing on the future therapeutic use of psychedelics. Neither step approves a drug or changes psilocybin's legal status, but together they show how the FDA is preparing for psychedelic drug applications.

What the NEJM framework says

The paper's authors are FDA drug center leaders: Michael Davis, Director of the Center for Drug Evaluation and Research (CDER); Teresa Buracchio, Director of the Office of Neuroscience; and Tiffany Farchione and Bernard Fischer of the Division of Psychiatry. According to coverage by RAPS and Psychedelic Alpha, they made four main points:

• Comparators: FDA is open to trials that compare a psychedelic against an active drug or a low dose, not only an inactive placebo.
• Functional unblinding: the agency recognizes that participants can often tell whether they got the real drug, which makes blinded trials harder to run.
• Durability: an initial approval could rest on showing efficacy over a clinically meaningful period. The authors gave examples of 12 weeks of efficacy plus 12 months of blinded follow-up.
• Safety programs: a Risk Evaluation and Mitigation Strategy (REMS) with elements to assure safe use may be required.

We could not open the NEJM article itself (DOI 10.1056/NEJMsb2609286), so this summary relies on those two reports.

What happened at the September 14 hearing

The FDA held a four-hour Part 15 public hearing at its White Oak campus under Docket FDA-2026-N-7542, first announced in the Federal Register on July 14, 2026. About 80 speakers addressed four broad topics: provider training and credentialing, patient safety, access and reimbursement, and data collection.

The FDA set limits on the discussion. It said it was not taking comment on drug scheduling or on the safety or efficacy of specific products. Written comments closed on October 5, 2026, and Psychedelic Alpha counted 609 submissions. Compass Pathways, which is developing a synthetic psilocybin treatment called COMP360, was the only late-stage developer that presented.

How this fits with the April executive order

Both steps come after Executive Order 14401, "Accelerating Medical Treatments for Serious Mental Illness," signed April 18, 2026 and published in the Federal Register on April 22. The order directs the FDA to award Commissioner's National Priority Vouchers to psychedelic drugs that hold Breakthrough Therapy designation, asks the FDA and DEA to set up a Right to Try pathway, directs at least $50 million through ARPA-H for partnerships with states, and asks the Attorney General to review Schedule I products that have completed Phase 3 trials so they can be rescheduled once the FDA approves them.

The order sets no deadlines, and its text does not mention psilocybin or MDMA by name. Ibogaine is the only drug it names. Six days after it was signed, on April 24, the FDA awarded priority vouchers to Compass Pathways (COMP360, for treatment-resistant depression), Usona Institute (psilocybin, for major depressive disorder) and Transcend Therapeutics (methylone, for PTSD).

What it means for patients now

Psilocybin is still a Schedule I drug under federal law, and no psilocybin medicine is FDA-approved as of October 20, 2026. The framework and hearing shape how future approvals might work, including who could give these treatments and under what safety rules, but they don't create any new legal access today.

For legal options that exist now, including clinical trials and state-licensed programs, see our guide to psilocybin therapy near you. For a roundup of the clinical evidence, see our psilocybin research page.